 Open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg 14C-radiolabelled AZD2281 KU-0059436 in patients with advanced or metastatic solid tumours. 